Phase 2RecruitingPriority 2 · High priorityNCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Plain-language summary
This Phase 2 trial is comparing brentuximab vedotin, brentuximab vedotin, and other medications against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 8 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
brentuximab vedotin (DRUG): MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg. | brentuximab vedotin (DRUG): LyP Brentuximab vedotin 0.9 mg/kg2 | brentuximab vedotin (DRUG): MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
- Drugs / treatments
- brentuximab vedotin, brentuximab vedotin, brentuximab vedotin
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details